Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global healthcare today.
From artificial intelligence to blockchain, the internet of things and regenerative medicine, Taiwanese firms – with the backing of an increasingly supportive research and funding ecosystem – are forging their way towards a disruptive future.
PharmaBoardroom’s latest report, Healthcare & Life Sciences Review Taiwan examines how Taiwan has leveraged its historical excellence in semiconductor manufacturing to excel in several technological niches within healthcare; why regulatory changes are making the Taiwanese market an ideal test-bed for global pharmaceutical firms’ most innovative products; and how the island has managed to position itself as one of Asia-Pacific’s most important clinical research destinations.
Other topics covered in this comprehensive new report include how start-ups and university spin-offs are increasingly able to access funding via listing on Taiwan’s stock exchanges; the island’s comprehensive IT infrastructure and how it is being leveraged; and the network of catapults and incubators being set up to propel Taiwanese research and innovation to the next level.
Overall, a picture emerges of a Taiwanese life sciences sector that – although small – seems ready to step up and contribute meaningfully on the world stage.
